Latest information on COVID-19
Support teaching, research, and patient care.
My career goal is to improve the health and lives of children with liver disease by making meaningful scientific contributions in the field of transplant hepatology that impact clinical care and improve outcomes for this patient population. I am an Associate Clinical Professor at Stanford University where I am the Director of Alagille Syndrome program and the Program Director for the Transplant Hepatology fellowship. My clinical and research interests lie at the intersection of the heart and the liver, specifically for Fontan associated liver disease and indications for combined heart-liver transplantation and support of our growing international referral program for patients with Alagille syndrome and their complex heart and liver needs. https://www.stanfordchildrens.org/en/service/alagille-syndromeI most recently was honored to receive the American Association for the Study of Liver Diseases (AASLD) and an international award from the International Pediatric Transplant Association (IPTA) both recognizing my contributions as an early career investigator. Finally, I remain committed to eliminating health disparities for children with liver disease on both an institutional and national level and galvanizing pediatric subspecialists to engage in advocacy to assure equal care for all children. I am the founder of our Stanford GI advocacy group: https://med.stanford.edu/gastroenterology/DiversityEquityInclusion/PedsGIAdvocacy.htmlI additionally serve as the inaugural Director of Policy in the Office of Child Health Equity at Stanford University.https://med.stanford.edu/childhealthequity/policy-participation.htmlYou can connect with me on social media: @NoelleEbelMD (Twitter)
Current projects include: -indications for combined heart-liver transplantation-mitigating perioperative bleeding during cardiac surgery in children with Alagille syndrome-congenital heart disease and liver transplantation-subspecialty advocacy
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
This study is designed to assess whether the investigational drug maralixibat, is safe and
well tolerated in children <12 months of age with Alagille Syndrome [ALGS] or Progressive
Familial Intrahepatic Cholestasis [PFIC].
View full details